Stephanie Gomez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stephanie Gomez has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Katherine B. Chiappinelli
The George Washington University 1 Department of Microbiology, Immunology and Tropical Medicine Washington, District of Columbia
27 shared publications - Paul Tran Austin
Department of Microbiology, Immunology and Tropical Medicine, The George Washington University Cancer Center, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia
24 shared publications - Alexander Solovyov
Computational Oncology, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
23 shared publications - Amir Hosseini
Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK
23 shared publications - Amit Manulal Oza
Princess Margaret Cancer Centre 2 Division of Medical Oncology and Hematology , Toronto, Canada
23 shared publications - Aneil Srivastava
Department of Microbiology, Immunology and Tropical Medicine, The George Washington University Cancer Center, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia
23 shared publications
Latest Publications
- Open Access
- 22 July 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3493
Author Correction: Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial
- 22 July 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3493
Open AccessAuthor Correction: Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial
- Open Access
- 30 June 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (7) , 2481-2493
Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial
Central nervous system (CNS) tumors are the deadliest cancers in children, highlighting the need for new therapies. The tumor-associated antigens (TAAs) WT1, PRAME and survivin are widely expressed by these tumors, and a manufacturing technique has been developed to target these intracellular TAAs using autologous, nongenetically engineered T cells. Here we therefore conducted ReMIND, an open-label, phase 1 adaptive dose-finding study to determine the safety/feasibility of autologous, systemically administered trivalent T cells targeting WT1, PRAME and survivin in children with CNS tumors. Eligible patients had newly diagnosed diffuse intrinsic pontine glioma without lymphodepletion (arm A, n = 16 enrolled, n = 11 infused) and relapsed/recurrent nonbrainstem CNS malignancies without (arm B, n = 28 enrolled, n = 18 infused) or with (arm C, n = 7 enrolled, n = 4 infused) lymphodepletion. Primary end points were safety, feasibility and maximum tolerated dose determination; secondary end points included preliminary efficacy and immunobiological correlates, including in vivo TAA-T persistence and systemic immune activation. Dose level 3 (8 × 107 cells per m2 per dose) was determined as the maximum tolerated dose. Treatment was well tolerated with fatigue and headache being the most common adverse events, although two possibly related serious adverse events of tumor swelling occurred. One grade 5 event in a patient with diffuse intrinsic pontine glioma with hydrocephalus, tumor edema and respiratory failure was categorized as a dose-limiting toxicity. Median overall survival for arm A was 13.7 months from diagnosis (range, 6.2-32.0) and median progression-free survival for arms B/C was 5.0 months from infusion (range, 0.5-51.6). Three patients in arms B/C are alive without disease at 31.8, 41.2 and 51.6 months without further treatment, including one complete response. This trial met safety/feasibility primary end points with some preliminary signals of efficacy. ClinicalTrials.gov registration: NCT03652545 .
- 30 June 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (7) , 2481-2493
Open AccessMulti-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial
Central nervous system (CNS) tumors are the deadliest cancers in children, highlighting the need for new therapies. The tumor-associated antigens (TAAs) WT1, PRAME and survivin are widely expressed by these tumors, and a manufacturing technique has been developed to target these intracellular TAAs using autologous, nongenetically engineered T cells. Here we therefore conducted ReMIND, an open-label, phase 1 adaptive dose-finding study to determine the safety/feasibility of autologous, systemically administered trivalent T cells targeting WT1, PRAME and survivin in children with CNS tumors. Eligible patients had newly diagnosed diffuse intrinsic pontine glioma without lymphodepletion (arm A, n = 16 enrolled, n = 11 infused) and relapsed/recurrent nonbrainstem CNS malignancies without (arm B, n = 28 enrolled, n = 18 infused) or with (arm C, n = 7 enrolled, n = 4 infused) lymphodepletion. Primary end points were safety, feasibility and maximum tolerated dose determination; secondary end points included preliminary efficacy and immunobiological correlates, including in vivo TAA-T persistence and systemic immune activation. Dose level 3 (8 × 107 cells per m2 per dose) was determined as the maximum tolerated dose. Treatment was well tolerated with fatigue and headache being the most common adverse events, although two possibly related serious adverse events of tumor swelling occurred. One grade 5 event in a patient with diffuse intrinsic pontine glioma with hydrocephalus, tumor edema and respiratory failure was categorized as a dose-limiting toxicity. Median overall survival for arm A was 13.7 months from diagnosis (range, 6.2-32.0) and median progression-free survival for arms B/C was 5.0 months from infusion (range, 0.5-51.6). Three patients in arms B/C are alive without disease at 31.8, 41.2 and 51.6 months without further treatment, including one complete response. This trial met safety/feasibility primary end points with some preliminary signals of efficacy. ClinicalTrials.gov registration: NCT03652545 .
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Table S2: Guide RNAs used for CRISPR gene editing in this study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Table S2: Guide RNAs used for CRISPR gene editing in this study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Figure S7 that shows the impact of viral mimicry conditioning on therapeutic approaches
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Figure S7 that shows the impact of viral mimicry conditioning on therapeutic approaches
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Figure S3 shows that p53 loss diminishes H3K9me3 at transcriptionally upregulated repetitive elements
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Figure S3 shows that p53 loss diminishes H3K9me3 at transcriptionally upregulated repetitive elements
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Table S4: Primer sequences used in this study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Table S4: Primer sequences used in this study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Figure S6 that shows Acquisition of viral mimicry tolerance affects antitumor adaptive immune responses
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Figure S6 that shows Acquisition of viral mimicry tolerance affects antitumor adaptive immune responses
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Figure S2 shows that Trp53 mutation facilitates transcriptional dysregulation of retrotransposons in murine oviductal epithelial cells and ovarian surface epithelial cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Figure S2 shows that Trp53 mutation facilitates transcriptional dysregulation of retrotransposons in murine oviductal epithelial cells and ovarian surface epithelial cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Table S3: Antibodies used in this study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Table S3: Antibodies used in this study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Table S1: Patient cohort characteristics
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Chronic Viral Mimicry Induction following p53 Loss Promotes Immune Evasion
Table S1: Patient cohort characteristics